In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

BACKGROUND: In patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), virus-specific cytotoxic T lymphocytes (CTLs) fail to eliminate HCC cells expressing HBV antigens. As the expression of viral antigen in HBV-associated HCC may decrease to allow tumor to escape immune attack...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qi, Tian, Ye, Li, Yanyan, Zhang, Wei, Cai, Wenxuan, Liu, Yaju, Ren, Yuefei, Liang, Zhaoduan, Zhou, Peipei, Zhang, Yajing, Bao, Yifeng, Li, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745518/
https://www.ncbi.nlm.nih.gov/pubmed/33323464
http://dx.doi.org/10.1136/jitc-2020-001748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745518/
https://www.ncbi.nlm.nih.gov/pubmed/33323464
http://dx.doi.org/10.1136/jitc-2020-001748

Ejemplares similares